Overview
- A peer‑reviewed study from the University of California, Riverside published Thursday, August 13, 2026, found that nanomolar concentrations of vanillin altered human embryonic stem cells so they lost pluripotency and biased toward endoderm.
- Laboratory tests showed the effect was driven by activation of the TRPV4 calcium channel because a TRPV4 antagonist or blocking antibody prevented the change.
- The researchers reported that higher, micromolar doses killed the cells while lower, nanomolar doses changed cell fate, and they said their data predict those low concentrations could reach an embryo after maternal vaping.
- Independent experts and the study authors caution these are in‑vitro results and stress that lab exposures differ from how a developing embryo would encounter vanillin in a pregnant person, so human‑relevant exposure and clinical studies are needed.
- The team recommends clinicians warn patients who are pregnant or planning pregnancy not to vape, urges regulators to consider mandatory ingredient disclosure for e‑liquids, and notes this finding is part of ongoing work on other flavorants such as menthol and WS‑23.